Due to the reduction of Pd-l1 expression after Itga2 suppression, anti-PD-1 antibody treatment manifested a stronger anti-tumor effect in the Itga2 knockdown group by slowing down tumor growth and improving the survival rate of tumor-bearing mice (Fig. 7d,e). This evidence concerns the gene ITGA2 and neoplasm.